Marketing-authorisation holder · United States
Azurity
57 medicines in 1 country, as authorisation holder.
Group structure
Part of
AzurityPharmaceutical groupOther companies in the group
Headquarters not stated1
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Medicines
Every medicine in the registers under its name, current ones first.
1–25 of 57
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ALTOPREV10mg | 20mg | 40mg | 60mg · Tablet, extended release | Lovastatin | United States | Not marketed | 2002 |
| ARYNTA10mg/ml · Solution | Lisdexamfetamine dimesylate | United States | Marketed | 2025 |
| AZMIRO200mg/ml (200mg/ml) · Solution | Testosterone | United States | Marketed | 2022 |
| BIDIL37.5mg; 20mg · Tablet | Hydralazine, Isosorbide dinitrate | United States | Marketed | 2005 |
| BRYNOVIN25mg base/ml · Solution | Sitagliptin | United States | Marketed | 2025 |
| DANZITEN71mg base | 95mg base · Tablet | Nilotinib | United States | Marketed | 2024 |
| DUAKLIR PRESSAIR0.4mg/inh; 0.012mg/inh · Powder, metered | Aclidinium bromide, Formoterol | United States | Marketed | 2019 |
| E.E.S.200mg base · Tablet, chewable | Erythromycin | United States | Not marketed | 1970 |
| EDARBI40mg medoxomil | 80mg medoxomil · Tablet | Azilsartan kamedoxomil | United States | Marketed | 2011 |
| EDARBYCLOR40mg medoxomil; 12.5mg | 40mg medoxomil; 25mg · Tablet | Azilsartan kamedoxomil, Chlorthalidone | United States | Marketed | 2011 |
| EPANED1mg/ml · Solution | Enalapril | United States | Marketed | 2016 |
| EPANED KIT1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · For solution | Enalapril | United States | Not marketed | 2013 |
| EPRONTIA25mg/ml · Solution | Topiramate | United States | Marketed | 2021 |
| ERYPED200mg base · Tablet, chewable | Erythromycin | United States | Not marketed | 1970 |
| ERYTHROCIN STEARATE125mg base | 250mg base | 500mg base · Tablet | Erythromycin | United States | Not marketed | 1964 |
| EVEKEO10mg | 5mg · Tablet | Amfetamine | United States | Marketed | 2012 |
| EVEKEO ODT10MG | 15MG | 2.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 20MG | 5MG · Tablet, orally disintegrating | Amfetamine | United States | Not marketed | 2019 |
| FERABRIGHT300mg iron/10ml (eq 30mg iron/ml) | 510mg iron/17ml (eq 30mg iron/ml) · Solution | Ferumoxytol | United States | Marketed | 2025 |
| FERAHEME510mg iron/17ml (eq 30mg iron/ml) · Solution | Ferumoxytol | United States | Marketed | 2009 |
| FIRVANQ KIT25mg base/ml | 50mg base/ml · For solution | Vancomycin | United States | Marketed | 2018 |
| FLEQSUVY25mg/5ml · Suspension | Baclofen | United States | Marketed | 2022 |
| GLEOSTINE100mg | 10mg | 40mg | 5mg · Capsule | Lomustine | United States | Marketed | 1976 |
| GLIADEL7.7mg · Implant | Carmustine | United States | Marketed | 1996 |
| GOLYTELY3350 227.1gm/packet; 2.82gm/packet; 6.36gm/packet; 5.53gm/packet; 21.5gm/packet | 3350 236gm/bot; 2.97gm/bot; 6.74gm/bot; 5.86gm/bot; 22.74gm/bot · For solution | Macrogol, Potassium chloride, Bicarbonate, Sodium chloride, Sodium sulfate anhydrous | United States | Marketed | 1984 |
| HORIZANT300mg | 600mg · Tablet, extended release | Gabapentin enacarbil | United States | Marketed | 2011 |